Mayo Clinic Article on Geron (GERN) Doeesn't Offer a Lot New - Needham & Company

December 6, 2013 9:34 AM EST Send to a Friend
Get Alerts GERN Hot Sheet
Price: $3.70 +13.85%

Rating Summary:
    3 Buy, 4 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 18 | New: 41
Trade GERN Now!
Join SI Premium – FREE
Geron Corporation (NASDAQ: GERN) is up 15% this morning after following an article yesterday by the Mayo Clinic describing the imetelstat data to be presented Monday at the American Society for Hematology (ASH) meeting. However, one analyst is not convinced that the articles has a lot of new info.

Needham & Company analyst Chad Messer states, "In so far as this article reflects the actual presentation, we don't see a whole lot that is new beyond the unprecedented efficacy reported by the company in November. We remain positively inclined towards the data but feel investors should wait for full presentation, as well as Geron's investor event, on Monday to understand the full story. Even then we may not know important details about the company's plans for further development of imetelstat in myelofibrosis."

For an analyst ratings summary and ratings history on Geron Corporation click here. For more ratings news on Geron Corporation click here.

Shares of Geron Corporation closed at $5.87 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, FDA, Momentum Movers

Related Entities

Needham & Company

Add Your Comment